Clinical Trials Directory

Trials / Terminated

TerminatedNCT00617162

Deep Brain Stimulation for Major Depressive Disorder

A Clinical Evaluation for the Management of Patients With Major Depressive Disorder, Single or Recurrent Episode, With Deep Brain Stimulation

Status
Terminated
Phase
N/A
Study type
Interventional
Enrollment
125 (actual)
Sponsor
Abbott Medical Devices · Industry
Sex
All
Age
21 Years – 70 Years
Healthy volunteers
Not accepted

Summary

This study is designed as a prospective, multi-centered, double-blind, randomized, controlled 12-month pivotal study to evaluate the safety and efficacy of the ANS Libra® Deep Brain Stimulation System for patients with major depressive disorder who have failed at least 4 treatments in the current episode. The primary outcome assessment will occur at 6 months: however, all patients will be followed for 1 year. A total of 201 patients will be randomized from up to 20 sites. Each potential patient will be pre-screened according to the inclusion/exclusion criteria. A narrative of what study participation entails, will be used to educate potential participants on study requirements. Prior to on-site baseline evaluations, the patient will sign the informed consent. Patients will then undergo 3 baseline evaluations, with each of these evaluations to occur no less than 2 weeks apart from each other. The first 2 baseline visit evaluations will be performed by separate psychiatrists in order to confirm the patient's diagnosis. All patients will be scheduled for surgery, to occur no less than two weeks and no more than 1 month after final baseline evaluation, to implant the ANS Libra® Deep Brain Stimulation system. After device implantation, patients will be randomly assigned to 1 of 2 groups in a 2:1 ratio (Active Treatment Group \& Control Group). After system implant (Week 0), the patient will return to clinic approximately 2 weeks after surgery for evaluation and treatment randomization into either Group 1 or Group 2 (Group 1 = Active Treatment Group; Group 2 = Control Group). Patient will then return to clinic for subsequent evaluations at 2 weeks, 4 weeks, 6 weeks, 8 weeks, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, and 1 year post system implantation.

Conditions

Interventions

TypeNameDescription
DEVICEDeep Brain Stimulation, Libra Deep Brain Stimulation SystemDBS Active Treatment Group - implanted with investigational device and activated for stimulation
DEVICEDeep Brain Stimulation, Libra Deep Brain Stimulation Systemimplanted with investigational device, but will not receive active stimulation for the first 6 months of the study

Timeline

Start date
2008-03-01
Primary completion
2014-06-01
Completion
2015-06-01
First posted
2008-02-15
Last updated
2024-04-08
Results posted
2024-04-08

Locations

13 sites across 3 countries: United States, Canada, United Kingdom

Source: ClinicalTrials.gov record NCT00617162. Inclusion in this directory is not an endorsement.